| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $41.5M | — | +77.6% |
| SG&A Expense | $17.7M | — | +101.5% |
| Operating Income | -$59.2M | — | -84.1% |
| Interest Expense | $1.2M | — | +106.8% |
| Net Income | -$77.1M | — | -230.2% |
| EPS (Basic) | -$0.71 | — | -163.0% |
| EPS (Diluted) | -$0.71 | — | -102.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $262.5M | +1.8% | +216.8% |
| Short-term Investments | $110.9M | -27.9% | -14.4% |
| Current Assets | $380.6M | -9.2% | +71.7% |
| Total Assets | $401.3M | -8.8% | +45.8% |
| Current Liabilities | $81.1M | +21.6% | +166.1% |
| Long-term Debt | $40.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$42.6M | — | -44.9% |
| Investing Cash Flow | $42.0M | — | +125.9% |
| Financing Cash Flow | $5.3M | — | +429.8% |
| +85.0% |
| Total Liabilities | $122.4M | +13.6% | +133.2% |
| Stockholders' Equity | $278.8M | -16.1% | +25.2% |